Compare ARK Genomic Revolution ETF (ARKG) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs iShares Core S&P 500 ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.55, while iShares Core S&P 500 ETF trades at $751.74. Which is the better fit depends on your goals.
| ARKG | IVV | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $43.57 | $763.10 |
52-Week Low | $23.09 | $624.65 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
IVV, tracking the S&P 500, trades at $758.39, up 0.43% on the day, with a bullish technical signal from moving averages and support near $751. The index is approaching record highs, driven by AI-led tech strength and robust earnings forecasts, though RSI levels indicate potential overbought conditions. A dividend of $2.00 is scheduled for June 2026.
The outlook remains positive given strong AI-driven earnings growth and institutional optimism, with targets like 8,250 cited by Yardeni Research (July 7, 2026). Risks include Fed policy shifts, geopolitical tensions, and high valuations; investors should focus on earnings momentum amid sector rotations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
